Advertisement

Topics

Global and Regional Postmenopausal Vaginal Atrophy Treatment Market Research Report 2017 [Report Updated: 09112017] Prices from USD $3500

02:29 EST 15 Nov 2017 | BioPortfolio Reports

Summary

Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.

Market Segment as follows:

By Region

AsiaPacific

North America

Europe

South America

Middle East Africa

By Type

Creams

Tablets

Patches

Rings

By Application

Topical Estrogen

Systemic Estrogen

Nonhormonal Therapy

By Company

Allergan

Pfizer

Shionogi

Novo Nordisk

Teva Pharmaceutical

Bayer.

The main contents of the report including:

Section 1:

Product definition, type and application, global and regional market overview;

Section 2:

Global and regional Market competition by company;

Section 3:

Global and regional sales revenue, volume and price by type;

Section 4:

Global and regional sales revenue, volume and price by application;

Section 5:

Regional export and import;

Section 6:

Company information, business overview, sales data and product specifications;

Section 7:

Industry chain and raw materials;

Section 8:

SWOT and Porter's Five Forces;

Section 9:

Conclusion.

Original Article: Global and Regional Postmenopausal Vaginal Atrophy Treatment Market Research Report 2017 [Report Updated: 09112017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Global and Regional Postmenopausal Vaginal Atrophy Treatment Market Research Report 2017 [Report Updated: 09112017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...